The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus

被引：5
作者：
Sharifi F. [1 ]
Hojeghani N. [2 ]
Mazloomzadeh S. [1 ]
Shajari Z. [1 ,3 ]
机构：
[1] Metabolic Diseases Research Centre, Zanjan University of Medical Sciences, Zanjan
[2] Department of Internal Medicine, Vali asr Hospital, Zanjan
[3] Zanjan Metabolic Diseases Research Centre, Vali-e-asr Hospital, Zanjan
来源：
Journal of Diabetes & Metabolic Disorders | / 12卷 / 1期
关键词：
Ezetimibe; Gemfibrozil; Postprandial hypertriglyceridemia; Type; 2; diabetes;
D O I：
10.1186/2251-6581-12-24
中图分类号：
学科分类号：
摘要：
Background: Postprandial hypertriglyceridemia in diabetes mellitus can be followed by endothelial dysfunction, impaired vascular compliance and increased cardiovascular complications. So focus on better control of postprandial hypertriglyceridemia is as important as controlling fasting triglyceride level in type 2 DM.Objective: We evaluated the effect of ezetimibe adding to fibrate or statin on postprandial hypertriglyceridemia.Methods: In a randomized controlled clinical trial, 47 subjects with type 2 diabetes and hypertiglyceridemia were enrolled and divided in three treatment groups including Gemfibrozil 1200mg/d + placebo(group A), Ezetimibe10mg/d + Gemfibrozile 1200mg/d(group B) or Ezetimibe10mg/d + Atorvastatin10mg/d (group C) for a 6- week period. Oral fat loading test were performed in the initiation and also at the end of the study and lipid profile and APOB were measured.Results: Fasting and postprandial serum triglyceride (TG) decreased significantly with all the three treatment groups with no difference between them in the percent of TG reduction. Although serum total cholesterol decreased significantly in all the three groups of treatment its reduction was more prominent in group C(-38.1% ± 11.2%in group C vs. -16.5% ± 19.6% and -7.2% ± 10.7% in groups B & A respectively, p < 0.0001 ). Fasting serum HDL increased significantly only by Gemfibrozil (23.4% ± 28.4% vs. 6.4% ± 18.9% and 1.8% ± 17.7%, p < 0.05 ). Fasting serum APOB was reduced only in ezetimibe containing groups (B &C).Conclusion: Adding ezetimibe to gemfibrozil has no additional effect on reducing postprandial TG but ezetimibe can potentiate the effect of low-dose atorvastatin on lowering TG and LDL-c. © 2013 Sharifi et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 31 条
[1]  
Hyson D., Rutledge J.C., Berglund L., Postprandial lipemia and cardiovascular disease, Curr Atheroscler Rep, 5, pp. 437-444, (2003)
[2]  
Carmena R., Type 2 diabetes, dyslipidemia, and vascular risk: Rationale and evidence for correcting the lipid imbalance, Am Heart J, 150, pp. 859-870, (2005)
[3]  
Steiner G., Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes, the Diabetes Atherosclerosis Intervention Study, a randomized study, Lancet, 10, 357, (2001)
[4]  
Elkeles R.S., Diamond J.R., Poulter C., Dhanjil S., Nicolaides A., Mahmood S., Richmond W., Mather H., Sharp P., Feher M., Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study, Diabetes Care, 21, pp. 641-648, (1998)
[5]  
Kosoglou T., Meyer I., Veltri E.P., Statkevich P., Yang B., Zhu Y., Mellars L., Maxwell S.E., Patrick J.E., Cutler D., Batra V.K., Melton B., Affrime M.B., Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin, Br J Clin Pharmaco, 54, pp. 309-319, (2002)
[6]  
Farnier M., Massimo Volpe M., Massaad R., Davies M.J., Allen C., Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease, Int J Cardiol, 102, pp. 327-332, (2005)
[7]  
Bozzetto L., Annuzzi G., DellaCorte G., Patti L., Cipriano P., Mangione A., Riccardi G., Rivellese A., Ezetimibe beneficiallyinfluencesfastingandpostprandialtriglyceride-rich lipoproteins intype2diabetes, Atherosclerosis, 217, pp. 142-148, (2011)
[8]  
IPAQ. Short last 7 days self-administered. The international physical activity questionnaire
[9]  
Harano Y., Miyawaki T., Nabiki J., Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia, Endocr J, 53, pp. 173-180, (2006)
[10]  
Koskinen P., Manttari M., Manninen V., Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study, Diabetes Care, 15, pp. 820-825, (1992)
1234